Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Update on the Use of Vonoprazan: A Competitive Acid Blocker.

× No keyword cloud information.

14 in total

1. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI.

Authors: David Y Graham; Hong Lu; Maria Pina Dore
Journal: Helicobacter Date: 2018-11-15 Impact factor: 5.753

Review 2. Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.

Authors: Rena Yadlapati; Kelli DeLay
Journal: Med Clin North Am Date: 2018-11-01 Impact factor: 5.456

Review 3. Update on the Management of Helicobacter pylori Infection.

Authors: Nasir Saleem; Colin W Howden
Journal: Curr Treat Options Gastroenterol Date: 2020-07-17

Review 4. Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.

Authors: Fahmi Shibli; Yoshitaka Kitayama; Ronnie Fass
Journal: Curr Gastroenterol Rep Date: 2020-03-17

Review 5. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.

Authors: David Y Graham; Maria Pina Dore; Hong Lu
Journal: Expert Rev Anti Infect Ther Date: 2018-08-23 Impact factor: 5.091

Review 6. Potent Acid Suppression with PPIs and P-CABs: What's New?

Authors: Richard H Hunt; Carmelo Scarpignato
Journal: Curr Treat Options Gastroenterol Date: 2018-12

Review 7. Rational Use of Pancreatic Enzymes for Pancreatic Insufficiency and Pancreatic Pain.

Authors: Gyanprakash A Ketwaroo; David Y Graham
Journal: Adv Exp Med Biol Date: 2019 Impact factor: 2.622

8. Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor.

Authors: Maria Pina Dore; Stefano Bibbò; Giovanni Mario Pes; Ruggero Francavilla; David Y Graham
Journal: Can J Infect Dis Med Microbiol Date: 2019-04-01 Impact factor: 2.471

9. Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.

Authors: Yoshikazu Kinoshita; Yuuichi Sakurai; Nobuyoshi Takabayashi; Kentaro Kudou; Takahiro Araki; Takuya Miyagi; Katsuhiko Iwakiri; Kiyoshi Ashida
Journal: Clin Transl Gastroenterol Date: 2019-11 Impact factor: 4.488

10. Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans.

Authors: Yoo-Seong Jeong; Min-Soo Kim; Nora Lee; Areum Lee; Yoon-Jee Chae; Suk-Jae Chung; Kyeong-Ryoon Lee
Journal: Pharmaceutics Date: 2021-05-29 Impact factor: 6.321